ValuEngine cut shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) from a sell rating to a strong sell rating in a report published on Thursday, July 6th.

Several other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and set a $6.00 target price on shares of HTG Molecular Diagnostics in a research note on Thursday, June 29th. Zacks Investment Research cut shares of HTG Molecular Diagnostics from a buy rating to a hold rating in a research note on Tuesday, May 16th. Rodman & Renshaw lifted their price objective on shares of HTG Molecular Diagnostics from $4.50 to $6.00 and gave the stock a buy rating in a research note on Tuesday, May 16th. Finally, Canaccord Genuity lifted their price objective on shares of HTG Molecular Diagnostics from $5.50 to $6.50 and gave the stock a hold rating in a research note on Wednesday, April 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. HTG Molecular Diagnostics presently has a consensus rating of Hold and an average target price of $5.75.

Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) traded up 0.42% during midday trading on Thursday, reaching $2.41. The company had a trading volume of 124,751 shares. The company has a 50 day moving average price of $3.37 and a 200-day moving average price of $3.31. The firm’s market capitalization is $25.64 million. HTG Molecular Diagnostics has a one year low of $1.20 and a one year high of $13.25.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Monday, May 15th. The medical research company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by $0.15. The company had revenue of $1.37 million for the quarter, compared to analysts’ expectations of $2.44 million. HTG Molecular Diagnostics had a negative net margin of 440.31% and a negative return on equity of 1,538.49%. On average, analysts anticipate that HTG Molecular Diagnostics will post ($2.25) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/07/16/htg-molecular-diagnostics-inc-nasdaqhtgm-downgraded-to-strong-sell-at-valuengine-updated.html.

Several institutional investors have recently added to or reduced their stakes in HTGM. Granahan Investment Management Inc. MA purchased a new position in HTG Molecular Diagnostics during the first quarter worth approximately $228,000. Two Sigma Securities LLC purchased a new position in HTG Molecular Diagnostics during the first quarter worth approximately $150,000. UBS Group AG purchased a new position in HTG Molecular Diagnostics during the first quarter worth approximately $137,000. Finally, Renaissance Technologies LLC boosted its position in HTG Molecular Diagnostics by 32.3% in the fourth quarter. Renaissance Technologies LLC now owns 58,200 shares of the medical research company’s stock worth $130,000 after buying an additional 14,206 shares in the last quarter. 31.30% of the stock is owned by hedge funds and other institutional investors.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related stocks with our FREE daily email newsletter.